CRBU (Caribou Biosciences) Tariff Resilience Score: 7/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
65 GF Score
Price $1.66
GF Value $1.68
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Tariff Resilience Score?

Caribou Biosciences CRBU -0.90% 65 Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus rates CRBU with a GF Score™ of 65/100 and a GF Value™ of $1.68 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,370 Biotechnology companies, Caribou Biosciences ranks better than 90.36% on this metric.

Caribou Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Caribou Biosciences has Caribou Biosciences has a diversified supply chain and operates in a sector with some tariff exemptions. Its focus on innovation and domestic market reduces direct tariff impact, providing moderate resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Caribou Biosciences might have Highly Resilient.

Caribou Biosciences  (NAS:CRBU) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Caribou Biosciences Tariff Resilience Score Related Terms

CRBU vs YDES, PRQR, CRBP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Caribou Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Tariff Resilience Score falls into.


CRBU
65GF Score
Caribou Biosciences Inc CRBU
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Caribou Biosciences (CRBU) has a Tariff Resilience Score of 7 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Caribou Biosciences ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Caribou Biosciences' Tariff Resilience Score too high?
Caribou Biosciences' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Caribou Biosciences' value of 7 is 75% above this industry median. Based on the distribution chart, Caribou Biosciences ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Tariff Resilience Score compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #132 out of 1370 companies for Tariff Resilience Score. This places Caribou Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Caribou Biosciences' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.68, compared to a current price of $1.66 — trading 1.5% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.66 is trading 1.5% below its estimated GF Value™ of $1.68. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Tariff Resilience Score: 7
  • GF Value™: $1.68 vs. price of $1.66 (1.5% below fair value)
  • GF Score™: 65/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score

Get the complete analysis for CRBU

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.66
Price
$1.68
GF Value